Nainu Firzan, Frediansyah Andri, Mamada Sukamto S, Permana Andi Dian, Salampe Mirnawati, Chandran Deepak, Emran Talha Bin, Simal-Gandara Jesus
Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Tamalanrea, Makassar 90245, Indonesia.
Research Center for Food Technology and Processing (PRTPP), National Research and Innovation Agency (BRIN), Yogyakarta 55861, Indonesia.
Heliyon. 2023 Jun 2;9(6):e16919. doi: 10.1016/j.heliyon.2023.e16919. eCollection 2023 Jun.
Currently, the incidence of metabolic disorders is increasing, setting a challenge to global health. With major advancement in the diagnostic tools and clinical procedures, much has been known in the etiology of metabolic disorders and their corresponding pathophysiologies. In addition, the use of and experimental models prior to clinical studies has promoted numerous biomedical breakthroughs, including in the discovery and development of drug candidates to treat metabolic disorders. Indeed, chemicals isolated from natural products have been extensively studied as prospective drug candidates to manage diabetes, obesity, heart-related diseases, and cancer, partly due to their antioxidant and anti-inflammatory properties. Continuous efforts have been made in parallel to improve their bioactivity and bioavailability using selected drug delivery approaches. Here, we provide insights on recent progress in the role of inflammatory-mediated responses on the initiation of metabolic disorders, with particular reference to diabetes mellitus, obesity, heart-related diseases, and cancer. In addition, we discussed the prospective role of natural products in the management of diabetes, obesity, heart-related diseases, and cancers and provide lists of potential biological targets for high throughput screening in drug discovery and development. Lastly, we discussed findings observed in the preclinical and clinical studies prior to identifying suitable approaches on the phytochemical drug delivery systems that are potential to be used in the treatment of metabolic disorders.
目前，代谢紊乱的发病率正在上升，给全球健康带来了挑战。随着诊断工具和临床程序的重大进步，人们对代谢紊乱的病因及其相应的病理生理学有了更多的了解。此外，在临床研究之前使用实验模型促进了众多生物医学突破，包括发现和开发治疗代谢紊乱的候选药物。事实上，从天然产物中分离出的化学物质已被广泛研究作为治疗糖尿病、肥胖症、心脏病和癌症的潜在候选药物，部分原因是它们具有抗氧化和抗炎特性。同时，人们一直在不断努力，通过选择药物递送方法来提高它们的生物活性和生物利用度。在此，我们深入探讨炎症介导反应在代谢紊乱发生中的作用的最新进展，特别提及糖尿病、肥胖症、心脏病和癌症。此外，我们讨论了天然产物在糖尿病、肥胖症、心脏病和癌症管理中的潜在作用，并提供了药物发现和开发中高通量筛选的潜在生物学靶点列表。最后，在确定适用于治疗代谢紊乱的植物化学药物递送系统的合适方法之前，我们讨论了临床前和临床研究中的发现。
